AbbVie Financials - Benzinga

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$265.08

-0.13-0.05%

At close: Sep 23, 5:00 PM EST

$265.08

N/A

After Hours: 4:19 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Dividends Compare Options Stock Report

AbbVie Financials

AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 Est

AbbVie (NYSE:ABBV) affirms FY2026 Adj EPS guidance from $13.87-$14.07 to $13.87-$14.07 vs $14.08 analyst estimate..

Benzinga Newsdesk

PRO
AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 Est

AbbVie (NYSE:ABBV) affirms Q3 Adj EPS guidance from $3.84-$3.88 to $3.84-$3.88 vs $3.84 analyst estimate..

Benzinga Newsdesk

PRO
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share

Benzinga Newsdesk

PRO
Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est

AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.

Benzinga Newsdesk

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Evette Mitkov

PRO
CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est

AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..

Benzinga Newsdesk